Celldex Therapeutics Inc.

Celldex Therapeutics Inc.

Celldex Therapeutics Inc.

Overview
Date Founded

1983

Headquarters

Perryville III Building,53 Frontage Road,Suite 220,Hampton, NJ 08827

Type of Company

Public

Employees (Worldwide)

137

Industries

Pharmaceuticals
Pension Funds & Sovereign Wealth
Hospitals & Patient Services
Biotechnology

Company Description

Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Contact Data
Trying to get in touch with decision makers at Celldex Therapeutics Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder, President, Chief Executive Officer & Director

Founder

Chief Financial Officer, Secretary, Treasurer & Senior Vice President

Chief Financial Officer, Secretary, Treasurer & Senior Vice President

Senior Vice President & Chief Commercial Officer

Chief Medical Officer & Senior Vice President

Senior Vice President, Regulatory Affairs

Senior Vice President & Chief Business Officer

Senior Vice President, Chief Product Development Officer

Senior Vice President-Corporate Affairs & Administration

Board of Directors

Principal Investigator, International Technical Assistance at American Association of Blood Banks

Co-Founder at Celldex Therapeutics Inc.

Former Managing Partner at Dechert LLP

Former Audit Partner at Ernst & Young LLP

Co-Founder at Reliant Pharmaceuticals LLC

Paths to Celldex Therapeutics Inc.
Potential Connections via
Relationship Science
You
Celldex Therapeutics Inc.
Recent Transactions
Details Hidden

Celldex Therapeutics Inc. raised money in a private placement transaction

Details Hidden

Celldex Therapeutics Inc. purchases Kolltan Pharmaceuticals, Inc. from HBM Partners AG, Osage Partners LLC, Elm Street Venture Advisors, Inc., Auven Therapeutics Management LLLP, Tichenor Ventures LLC, Sectoral Asset Management Inc (Private Equity)

Details Hidden

Celldex Therapeutics Inc. issued Common Stock

Transaction Advisors
Underwriter

Advised onCelldex Therapeutics Inc. issued Common Stock

Underwriter

Advised onCelldex Therapeutics Inc. issued Common Stock

Auditor

Advised onCelldex Therapeutics Inc. issued Common Stock

Legal Advisor

Advised onCelldex Therapeutics Inc. issued Common Stock

Managing Director

Advised onCelldex Therapeutics Inc. issued Common Stock

Underwriter

Advised onCelldex Therapeutics Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Publicist

Founder at 1AB Media

Publicist

Founder at 1AB Media

Clients

The Rockefeller University (the University) is a world renowned center for research (see schedule O) and graduate education in the biomedical sciences, chemistry, bioinformatics, and physics. The University's 77 laboratories conduct both basic and clinical research and study a diverse range of biological and biomedical problems with the mission of improving the understanding of life for the benefit of humanity. Laboratories are loosely clustered in six research areas, including biochemistry, structural biology, and chemistry; medical sciences and human genetics; molecular, cell, and developmental biology; immunology, virology, and microbiology; neuroscience; and physics and mathematical biology. The University does not charge tuition. Its revenues are derived primarily from investment income, government grants and contracts, and private gifts and grants.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.

Key Stats and Financials As of 2018
Market Capitalization
$32.3M
Total Enterprise Value
$-62.9M
Earnings Per Share
$-14.48
Revenue
$9.54M
Total Equity
$124M
Enterprise Value Sales
-6.6x
TEVNet Income
0.42x
Debt TEV
0x
EBITDAMargin
-761.2%
Total Debt
$0
EBITDA
$-72.6M
Net Profit
$-151M
Three Year Compounded Annual Growth Rate Of Revenue
20.29%
Five Year Compounded Annual Growth Rate Of Revenue
18.33%
Non-Profit Donations & Grants
$5,000 - $10K
2008
Suppliers
Ambio Holdings, Inc. Holding Companies | North Augusta, SC

Ambio Holdings, Inc. operates as a pharmaceutical company which focuses on complex peptides. It develops processes for manufacturing peptides at small to large scale as active pharmaceutical ingredients used in New Chemical Entities and generic peptides by clients worldwide. The company was founded by Chris J. Bai in 2014 and is headquartered in North Augusta, SC.

Amgen, Inc. Hospitals & Patient Services | Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Celldex Therapeutics Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Celldex Therapeutics Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Celldex Therapeutics Inc..